Announcements Trials
Browse Landscape

Phase

Phase 1/2 2

Status

Recruiting 1Completed 1

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Gynecologic 2Breast 2Thoracic 1Genitourinary 1Gastrointestinal 1CNS 1

Conditions

Triple Negative Breast Neoplasms 14Breast Neoplasms 8Carcinoma, Non-Small-Cell Lung 6Urinary Bladder Neoplasms 4Endometrial Neoplasms 3Carcinoma, Transitional Cell 3Neoplasm Metastasis 2Lung Neoplasms 2Carcinoma, Ovarian Epithelial 2Uterine Cervical Neoplasms 1Triple Negative Locally Advanced Non-resectable Breast Cancer 1Solid Tumor 1Small Cell Lung Carcinoma 1Prostatic Neoplasms, Castration-Resistant 1Parkinson Disease 4, Autosomal Dominant Lewy Body 1Pancreatic Neoplasms 1Ovarian Neoplasms 1Neoplasms 1Metastatic Urothelial Cancer 1Metastatic Solid Tumors 1Locally Advanced or Metastatic Unresectable Urothelial Cancer 1Liver Failure 1Glioblastoma 1Fallopian Tube Neoplasms 1Extensive Stage Small Cell Lung Cancer (ES-SCLC) 1Esophageal Neoplasms 1Carcinoma, Renal Cell 1Carcinoma, Hepatocellular 1Advanced Solid Tumors 1

Interventions

Paclitaxel 32Carboplatin 23liposomal doxorubicin 14pembrolizumab 12Topotecan 10Bevacizumab 10Gemcitabine 9mirvetuximab soravtansine 8olaparib 6Cisplatin 61-dodecylpyridoxal 6rucaparib 5Nivolumab 5Cyclophosphamide 5oregovomab 4farletuzumab 3catumaxomab 3Standard of Care 3Irinotecan 3Fulvestrant 3CCV-AV protocol 3talazoparib 2sacituzumab govitecan 2ribociclib 2phenoxodiol 2pegfilgrastim 2pazopanib 2palbociclib 2niraparib 2fludarabine 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
INDUSTRY × Carcinoma, Ovarian Epithelial × sacituzumab govitecan × Clear all
NCT05867251 2025-11-19

Study of AVZO-021 in Patients With Advanced Solid Tumors

Avenzo Therapeutics, Inc.

Phase 1/2 Recruiting
430 enrolled
BreastGynecologic

Carcinoma, Ovarian Epithelial, Breast Neoplasms, Fallopian Tube Neoplasms, Endometrial Neoplasms, Triple Negative Breast Neoplasms

NCT01631552 2021-08-12

Study of Sacituzumab Govitecan-hziy (IMMU-132) in Adults With Epithelial Cancer

Gilead Sciences

Phase 1/2 Completed
515 enrolled 28 charts 1 FDA
BreastCNSGastrointestinalGenitourinaryGynecologicThoracic

Carcinoma, Ovarian Epithelial, Urinary Bladder Neoplasms, Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Uterine Cervical Neoplasms, Esophageal Neoplasms, Glioblastoma, Carcinoma, Hepatocellular, Pancreatic Neoplasms, Endometrial Neoplasms, Small Cell Lung Carcinoma, Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡